Natural history of venous thromboembolism

Circulation

Volumn 107, Issue SUPPL. 23, 2003, Pages

  Kearon, Clive ^a  

^a HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

Embolism; Epidemiology; Risk factors; Thrombosis; Veins

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY;

ACUTE DISEASE; CANCER; DISEASE COURSE; DISEASE SEVERITY; GENERAL SURGERY; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG EMBOLISM; MORTALITY; POSTOPERATIVE COMPLICATION; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROBABILITY; PULMONARY HYPERTENSION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VEIN THROMBOSIS;

DISEASE PROGRESSION; HUMANS; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0037704209     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000078464.82671.78     Document Type: Review

References (141)

1. Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. Br J Radiol. 1971;44:653-663.
2. Kakkar VV, Howe CT, Flanc C, et al. Natural history of postoperative deep-vein thrombosis. Lancet. 1969;2:230-232.
3. Cogo A, Lensing AWA, Prandoni P, et al. Distribution of thrombosis in patients with symptomatic deep-vein thrombosis: implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med. 1993;153:2777-2780.
4. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94:439-444.
5. McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest. 1974;65:534-543.
6. Alpert JS, Smith R, Carlson J, et al. Mortality in patients treated for pulmonary embolism. JAMA. 1976;236:1477-1480.
7. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest. 2002;122:1440-1456.
8. Flanc C, Kakkar VV, Clarke MB. The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen. Br J Surg. 1968;55:742-747.
9. Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop Related Res. 1991;273:125-130.
10. Kakkar VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975;II:45-51.
11. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997;77:26-31.
12. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224-228.
13. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North Am Fragmin Trial Investigators. Arch Intern Med. 2000;160:2208-2215.
14. Douketis JD, Eikelboom JW, Quinlan DJ, et al. I. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 2002;162:1465-1471.
15. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525-1531.
16. 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost. 1989;62:830-834.
17. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329-1335.
18. Bounameaux H, Huber O, Khabiri E, et al. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg. 1993;128:326-328.
19. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001;83-A:336-345.
20. Kearon C, Julian JA, Newman TE, et al., for the McMaster Diagnostic Imaging Practice Guidelines Initiative. Non-invasive diagnosis of deep vein thrombosis. Ann Intern Med. 1998;128:663-677.
21. Fraser DG, Moody AR, Morgan PS, et al. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med. 2002;136:89-98.
22. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anti-coagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985;2:515-518.
23. Heijboer H, Buller HR, Lensing AWA, et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med. 1993;329:1365-1369.
24. Doyle DJ, Turpie AGG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med. 1987;107:441-445.
25. Moser KM, Fedullo PF, LittleJohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA. 1994;27:223-225.
26. Nielsen HK, Husted SE, Krusell LR, et al. Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med. 1994;235:457-461.
27. Huisman MV, Buller HR, ten Cate J, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest. 1989;95:498-502.
28. Dorfman GS, Cronan JJ, Tupper TB, et al. Occult pulmonary embolism: a common occurrence in deep venous thrombosis. AJR. 1987;148:263-266.
29. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985;88:819-828.
30. The PIOPED investigators. Value of the ventilation perfusion scan in acute pulmonary embolism. JAMA. 1990;263:2753-2759.
31. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
32. Nielsen HK, Husted SE, Krusell LR, et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study. Thromb Res. 1994;73:215-226.
33. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1:1309-1312.
34. Coon WW, Willis PW. Recurrence of venous thromboembolism. Surgery. 1973;73:823-827.
35. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
36. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340:873-876.
37. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
38. Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
39. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
40. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis. Thromb Haemost. 1994;72:191-197.
41. Agnelli G, Mancini GB, Biagini D. The rationale for long-term prophylaxis of venous thrmoboembolism. Orthopedics. 2000;23:s643-s646.
42. Kalodiki E, Domjan J, Nicolaides AN, et al. V/Q defects and deep venous thrombosis following total hip replacement. Clin Radiol. 1995;50:400-403.
43. Philbrick JT, Becker DM. Calf deep venous thrombosis: a wolf in sheep's clothing? Arch Intern Med. 1988;148:2131-2138.
44. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995;108:978-981.
45. Bell WR, Simon TL. Current status of pulmonary embolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J. 1982;103:239-261.
46. Morganthaler TI, Ryu JH. Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc. 1995;70:417-424.
47. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159:445-453.
48. Bergqvist D, Lindblad B. A 30 year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. 1985;72:105-108.
49. Rasmussen MS, Wille-Jorgensen P, Jorgensen LN. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg. 1995;169:214-216.
50. Stein PD, Henry JW, Relyea B. Untreated patients with pulmonary embolism: outcome, clinical, and laboratory assessment. Chest. 1995;107:931-935.
51. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458-462.
52. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996;100:269-277.
53. Hutten BA, Prins M, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncology. 2000;18:3078-3083.
54. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84:805-810.
55. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
56. Holmstrom M, Lindmarker P, Granqvist S, et al. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. Thromb Haemost. 1997;78:803-807.
57. Heijboer H, Jongbloets LMM, Buller HR, et al. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis. Acta Radiologica. 1992;33:297-300.
58. Prandoni P, Cogo A, Bernardi E, et al. A simple ultrasound approach for detection of recurrent proximal vein thrombosis. Circulation. 1993;88:1730-1735.
59. Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002;87:515-522.
60. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955-960.
61. Jay R, Hull R, Carter C, et al. Outcome of abnormal impedance plethysmography results in patients with proximal-vein thrombosis: frequency of return to normal. Thromb Res. 1984;36:259-263.
62. Huisman MV, Büller HR, ten Cate JW. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch Intern Med. 1988;148:681-683.
63. Hirsh J, Lensing A. Thrombolytic therapy for deep vein thrombosis. Int Angiol. 1996;5:S22-S25.
64. Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg. 1979;66:838-843.
65. Turpie AGG, Levine MN, Hirsh J, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Chest. 1990;97:172S-175S.
66. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after thrombolytic treatment of deep vein thrombosis. J Am Coll Cardiol. 2000;36:1336-1343.
67. Caps MT, Manzo RA, Bergelin RO, et al. Venous valvular reflux in veins not involved at the time of acute deep vein thrombosis. J Vasc Surg. 1995;22:524-531.
68. Heldal M, Seem E, Sandset PM, et al. Deep vein thrombosis: a 7-year follow-up study. J Intern Med. 1993;234:71-75.
69. Biguzzi E, Mozzi E, Alatri A, et al. The post-thrombotic syndrome in young women: retrospective evaluation of prognostic factors. Thromb Haemost. 1998;80:575-577.
70. Ginsberg JS, Turkstra F, Buller HR, et al. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med. 2000;160:669-672.
71. Lindhagen A, Bergqvist D, Hallbook T, et al. Venous function five to eight years after clinically suspected deep venous thrombosis. Acta Med Scand. 1985;217:389-395.
72. Lindner DJ, Edwards JM, Phinney ES, et al. Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg. 1986;4:436-442.
73. Strandness DE, Langlois Y, Cramer C, et al. Long-term sequelae of acute venous thrombosis. JAMA. 1983;250:1289-1292.
74. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. Am J Surg. 1985;150:54-63.
75. Kahn SR, Solymoss S, Lamping DL, et al. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. J Gen Intern Med. 2000;15:425-429.
76. Prandoni P, Lensing AW, Prins MH, et al. Which is the outcome of the post-thrombotic syndrome? [letter] [published erratum appears in Thromb Haemost. 1999;82:X11] Thromb Haemost. 1999;82:1358.
77. Brandjes DPM, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349:759-762.
78. Cockett FB, Lea Thomas M, Negus D. Iliac vein compression. Its relation to iliofemoral thrombosis and the post-thrombotic syndrome. BMJ. 1967;2:14-19.
79. Cockett FB, Lea Thomas M. The iliac compression syndrome. Br J Surg. 1965;52:816-821.
80. Qvarfordt P, Eklof B, Ohlin P, et al. Intramuscular pressure, blood flow, and skeletal muscle metabolism in patients with venous claudication. Surgery. 1984;95:191-195.
81. Christenson JT, Al-Hassan HK, Shawa NJ. Subcutaneous and intra-muscular pressures in the post-phlebitic limb. Scand J Clin Lab Invest. 1986;46:137-141.
82. Goldhaber SZ, Visni L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.
83. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101:2817-2822.
84. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:227-229.
85. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339:93-104.
86. Dalen JE, Alpert JS, Hirsh J. Thrombolytic therapy for pulmonary embolism. Is it effective? Is it safe? When is it indicated? Arch Intern Med. 1997;157:2550-2556.
87. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 2000;102:211-217.
88. Goldhaber SZ, Haire WD, Feldstein ML, et al. Aleptase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507-511.
89. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134:479-487.
90. Miller RL, Das S, Anandarangam T, et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. Chest. 1998;113:665-670.
91. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
92. van Beek E Jr., Kuijer PMM, Buller HR, et al. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med. 1997;157:2593-2598.
93. Ribeiro A, Lindmarker P, Johnsson H, et al. Pulmonary embolism. One year follow-up with echocardiography doppler and five-year survival analysis. Circulation. 1999;99:1325-1330.
94. Wicki J, Perrier A, Perneger TV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 2000;84:548-552.
95. Kniffin WD Jr., Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861-866.
96. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb Haemost. 2002;88:407-414.
97. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol. 1971;28:288-294.
98. Dalen JE, Banas JS, Brooks HL, et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med. 1969;280:1194-1199.
99. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
100. Blackmon JR, Sautter RD, Wagner HN. Urokinase pulmonary embolism trial: phase I results. JAMA. 1970;214:2163-2172.
101. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acule pulmonary embolism. Chest. 1990;98:1473-1479.
102. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest. 1990;97:528-533.
103. Dalla-Volta S, Palla A. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol. 1992;20:520-526.
104. Paraskos JA, Adelstein SJ, Smith RE, et al. Late prognosis of acute pulmonary embolism. N Engl J Med. 1973;289:55-58.
105. Hall RJC, Sutton GC, Kerr IH. Long-term prognosis of treated acute massive pulmonary embolism. Br Heart J. 1977;39:1128-1134.
106. Riedel M, Stanek V, Widimsky J. Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151-158.
107. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465-1472.
108. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453-2460.
109. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.
110. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
111. Schulman S. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group. Wien Med Wochenschr. 1999;149:66-69.
112. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Anna Rev Med. 2000;51:169-185.
113. Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost. 1999;81:684-689.
114. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566-569.
115. Kryle P, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
116. Ridker PM, Miletich JP, Stampfer MS, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
117. 506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
118. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
119. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624-628.
120. Miles JS, Miletich JP, Goldhaber SZ, et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001;37:215-218.
121. Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329-3333.
122. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338:409-415.
123. White RH, Zhou H, Kim J, et al. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med. 2000;160:2033-2041.
124. Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group. J Intern Med. 2000;247:601-606.
125. Kearon C. Duration of therapy for acute venous thromboembolism. Clin Chest Med. 2003;24:63-72.
126. Turkstra F, Karemaker R, Kuijer PMM, et al. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost. 1999;81:345-348.
127. Margaglione M, Brancaccio V, De Lucia D, et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest. 2000;118:1405-1411.
128. Flordal PA, Bergqvist D, Ljungstrom KG, et al. Clinical relevance of the fibrinogen uptake test in patients having general abdominal surgery - relation to major thromboembolism and mortality. Thromb Res. 1995;80:491-497.
129. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med. 1988;318:1162-1173.
130. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-246.
131. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154:164-167.
132. Bergqvist D, Agnelli G, Cohen AF, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980.
133. Hull R, Hirsh J, Sackett DL, et al. Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N Engl J Med. 1977;296:1497-1500.
134. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983;98:891-899.
135. Kruit WHJ, de Boer AC, Sing AK, et al. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med. 1991;230:333-339.
136. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med. 1998;129:1044-1049.
137. Hull RD, Raskob GE, Coates G, et al. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med. 1989;149:2549-2555.
138. Pinede L, Duhaut P, Cucherat M, et al. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med. 2000;247:553-562.
139. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332-338.
140. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost. 1996;75:859.
141. Schulman S. Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemost. 1997;78:693-698.